OPKO Health (NASDAQ:OPK) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of OPKO Health (NASDAQ:OPK - Free Report) to a strong-buy rating in a report issued on Tuesday,Zacks.com reports.

OPK has been the topic of a number of other research reports. Wall Street Zen lowered shares of OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. HC Wainwright restated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research report on Monday, April 7th. JPMorgan Chase & Co. started coverage on shares of OPKO Health in a research report on Friday, April 25th. They set a "neutral" rating on the stock. Finally, Barrington Research reiterated an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, OPKO Health has a consensus rating of "Moderate Buy" and a consensus target price of $2.75.

OPKO Health Stock Performance

OPK traded up $0.01 on Tuesday, reaching $1.37. The company had a trading volume of 1,110,776 shares, compared to its average volume of 3,873,237. OPKO Health has a fifty-two week low of $1.21 and a fifty-two week high of $2.04. The stock has a market cap of $1.08 billion, a P/E ratio of -19.50 and a beta of 1.34. The company's fifty day moving average is $1.32 and its 200 day moving average is $1.49. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.28 and a current ratio of 2.49.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. The company had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. During the same quarter last year, the company posted ($0.12) EPS. The firm's quarterly revenue was down 13.7% on a year-over-year basis. As a group, analysts predict that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OPKO Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its stake in OPKO Health by 68.7% in the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock valued at $1,347,000 after purchasing an additional 373,032 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of OPKO Health during the first quarter valued at $585,000. Bank of America Corp DE raised its stake in shares of OPKO Health by 94.7% during the fourth quarter. Bank of America Corp DE now owns 581,582 shares of the biotechnology company's stock valued at $855,000 after acquiring an additional 282,844 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of OPKO Health by 136.1% during the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock valued at $2,422,000 after acquiring an additional 949,671 shares during the last quarter. Finally, Norges Bank bought a new position in shares of OPKO Health during the fourth quarter valued at $1,657,000. Institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.